跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT00196989
NCT00196989已完成2 期

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of Oral GW677954 as a Monotherapy for 12 Weeks Duration in Patients With Type 2 Diabetes Mellitus

GlaxoSmithKline144 个研究点 分布在 2 个国家目标入组 448 人开始时间: 2005年9月最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
448
试验地点
144
主要终点
Percentage change from Baseline (Day 1) in glycated hemoglobin (HbA1c) levels at Week 16 as a measure of improvement in glucose control
研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).

详细描述

A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Study To Evaluate Efficacy, Safety And Tolerability Of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 Mg Once A Day) As A Monotherapy (Diet and/or exercise treated) Or As An Add-On To Metformin For 16 Weeks Duration In Subjects With Type 2 Diabetes Mellitus

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 70 Years（Adult, Older Adult）
性别
All
接受健康志愿者
否

入选标准

  • 未提供

排除标准

  • •Metabolic Disease including:
  • •Diagnosis of Type 1 diabetes mellitus
  • •Uncorrected thyroid dysfunction. (NOTE: subjects with hypothyroidism on a stable dose of thyroid replacement therapy for at least 1 month prior to Screening, and who have a screening thyroid stimulating hormone (TSH) within the upper limit of normal may participate).
  • •Significant weight gain or loss (defined as > 5% of total body weight) within the 3 months prior to Screening.
  • •Previous use of insulin for treatment of hyperglycemia within 3 months of Screening.
  • •History of recent clinically significant cardiovascular disease including:
  • •History or ECG evidence of prior myocardial infarction within 6 months prior to Screening.
  • •Current unstable angina or history of unstable angina in past 6 months.
  • •Coronary revascularization including percutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft (CABG) surgery that is either planned or occurred in the 6 months prior to Screening.
  • •Clinically significant arrhythmia or valvular heart disease.
  • •Congestive heart failure (CHF) with New York Heart Association (NYHA) Class II-IV symptoms (see Section 15.4, Appendix 4).
  • •Blood pressure > 160/100 mmHg or resting heart rate > 100 bpm. Note: subjects using antihypertensives [e.g., beta blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers and diuretics] must be on stable doses during the 30 days prior to Screening and during the trial.
  • •Has a QTc interval (Bazett's) > 440 msec in males and > 450 msec in females at Screening.
  • •Clinically significant ECG abnormalities which, in the opinion of the Investigator, may affect the interpretation of safety data, or which otherwise, contraindicates participation in a clinical trial with a new chemical entity.
  • •History of chronic pancreatitis.
  • •Familial hypercholesterolemia.
  • •TGs ≥800 mg/dL (8.96 mmol/L) at Screening.
  • •Serum creatinine at screening > 1.4 mg/dL (124 µmol/L) for women, or > 1.5 mg/dL (133 µmol/L) for men.
  • •Clinically significant anemia defined by hemoglobin concentrations <12.0 g/dL or < 120.0 g/L for males and < 11.0 g/dL or < 110.0 g/L for females.
  • •History of significant co-morbid diseases (e.g., cholelithiasis, gastrointestinal disease, etc.) that would preclude participation in the study.
  • •Documented history of hepato-biliary disease including a history of, or positive laboratory results for hepatitis (hepatitis B surface antigen and/or hepatitis C antibody) at Screening, and/or clinically significant hepatic enzyme elevation including:
  • •Any one of the following enzymes greater than 2.5 times the upper limit of normal (ULN) value at Screening:
  • •Alanine aminotransferase (ALT)
  • •Aspartate aminotransferase (AST)
  • •Alkaline phosphatase (ALP)
  • •Total or direct bilirubin > 1.5 times the ULN at Screening, unless consistent with presumed or diagnosed Gilbert's disease.
  • •History of metabolic acidosis, rhabdomyolysis, myalgia, myositis or myopathy after taking statins or fibrates.
  • •Any subject who has withdrawn therapy due to AEs after taking a PPARγ or a PPARα/γ dual agonist, either marketed (e.g., troglitazone, rosiglitazone or pioglitazone) or under current or previous clinical investigation.
  • •Signs or symptoms of myositis at Screening (or upon 1 repeat test), and/or creatinine phosphokinase (CPK)≥3.0 times ULN
  • •Is currently taking or has taken any of the following medications in the 3 months prior to the pre-screening visit:
  • •Anti-obesity agents (including fat absorption blocking agents)
  • •St. John's Wort
  • •Warfarin and other oral anticoagulants (excluding aspirin and non-steroidal anti-inflammatory drugs)
  • •Oral or injectable corticosteroids (inhaled and intranasal steroids are acceptable)
  • •Use of antidiabetic agents (other than metformin) in the 2 months prior to the pre-screening visit.
  • •Use of TZDs in the 3 months prior to the pre-screening visit.
  • •Methotrexate, cyclosporine or monoclonal antibodies (e.g., alemtuzumab, gemtuzumab ozogamicin, rituximab, trastuzumab, ibritumomab, tiuxetan) for rheumatoid arthritis or psoriasis.
  • •Atypical antipsychotic medications [e.g., aripiprazole (Abilify), risperidone (Risperdal), clozapine (Clozaril), olanzapine (Zyprexa), quetiapine (Seroquel), and ziprasidone (Geodon)].
  • •Antiretroviral drugs
  • •Use of lipid lowering agents within 3 months prior to the pre-screening visit. This includes statins, fibrates, ezetimibe (Zetia), niacin and bile acid sequestrants.
  • •Monoamine oxidase inhibitors
  • •History of cancer except for the following:
  • •Basal cell carcinoma or superficial squamous cell carcinoma treated by local excision.
  • •Cervical cancer in situ treated definitively more than 6 months prior to screening.
  • •Women who are lactating, pregnant, or planning to become pregnant.
  • •Known immediate or delayed hypersensitivity reaction or idiosyncrasy to any drug chemically related to the study drug.
  • •Known allergy to any of the capsule excipients, or history of drug or other allergy, which, in the opinion of the responsible study physician, contradicts participation. Hypersensitivity to metformin or any of its components (for subjects entering on metformin).
  • •Has a history of substance and/or alcohol abuse within the past year as determined by the Investigator at screening or during treatment:
  • •Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
  • •History of alcohol abuse defined as an average weekly intake of greater than 21 units or an average daily intake of greater than 3 units (males) or defined as an average weekly intake of greater than 14 units or an average daily intake of greater than 2 units (females). One unit is equivalent to a half-pint of beer or 1 measure of spirits or 1 glass of wine.
  • 另有 6 项未显示

结局指标

主要结局

Percentage change from Baseline (Day 1) in glycated hemoglobin (HbA1c) levels at Week 16 as a measure of improvement in glucose control

时间窗: Week (W) 16

Improvement in glucose control was measured by means of reduction in glycated hemoglobin (Hb) levels in blood.

次要结局

  • Percentage of participants achieving target HbA1c levels at Weeks 4, 8, 12, and 16(Weeks 4, 8, 12, and 16)
  • Percentage of participants achieving a decrease from Baseline (Day 1) of >=30 mg/dL [1.66 mmol/L] in FPG at Weeks 1, 2, 4, 6, 8, 12 and 16(Weeks 1, 2, 4, 6, 8, 12, and 16)
  • Percentage change from Baseline (Day 1) in fasting HbA1c levels at Weeks 4, 8 and 12(Weeks 4, 8, and 12)
  • Change from Baseline (Day 1) in fasting fructosamine at Weeks 2 and 4(Baseline (Day 1), W2, W4)
  • Percentage change from Baseline (Day 1) in non-HDL-C based on log-transformed data at Week 16(At Week 16)
  • Change from Baseline (Day 1) in Apo B/TC, TC/HDL-C, and LDL-C/Apo B ratio at Week 16(At Week 16)
  • Change from Baseline (Day 1) in fasting plasma glucose (FPG) at Weeks 1, 2, 4, 6, 8, 12 and 16(W1, W2, W4, W6, W8, W12, and W16)
  • Percentage of participants achieving a decrease in HbA1c of >= 0.7% from Baseline (Day 1) at Weeks 4, 8, 12 and 16(Baseline (Day 1), Weeks 4, 8, 12, and 16)
  • Percentage of participants achieving target range of FPG at Weeks 1, 2, 4, 6, 8, 12 and 16(Weeks 1,2, 4, 6, 8, 12, and 16)
  • Percentage change from Baseline (Day 1) in very low density lipoprotein-cholesterol (VLDL-C), apolipoprotein AI (Apo AI), AII, and B at Week 16.(At Week 16)
  • Change from Baseline (Day 1) in hemoglobin at Week 16(At Week 16)
  • Change from Baseline (Day 1) in 12 lead electrocardiogram (ECG) measures including PR interval, QT interval, QTc interval and QRS duration at Week 16(Week 16)
  • Number of participants with adverse events (AEs) and serious adverse events (SAEs) over period(Up to 16 weeks)
  • Number of participants with absolute Troponin-I (cTnI) levels over period(Up to 16 weeks)
  • Ratio to the Baseline (percentage change) of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG), and free fatty acids (FFA) at Weeks 2, 4, 8, 12, and 16(Baseline (Day 1), Weeks 2, 4, 8, 12, and 16)
  • Change from Baseline (Day 1) in systolic and diastolic blood pressure (SBP and DBP) at Week 16(At Week 16)
  • Change from Baseline (Day 1) in heart rate at Week 16(Week 16)
  • Change from Baseline (Day 1) in body weight at Week 16(Week 16)
  • Number of participants with intensity of hypoglycemic events as a measure of ophthalmic assessment(Up to 16 weeks)
  • Change from Baseline (Day 1) in HOMA-S at Week 16(Week 16)
  • Change from Baseline (Day 1) in hematocrit at Week 16(Wekk 16)
  • Number of participants with clinical hematology, chemistry, urinalysis, exploratory cardiac parameters of potential clinical concern (PCC) along with serum pregnancy test over period(Upto 16 weeks)
  • Number of participants with hypoglycemic events as a measure of ophthalmic assessment(Up to 16 weeks)
  • Change from Baseline (Day 1) in phosphocreatine kinase (Creatine kinase-MB) over period(Up to 16 weeks)
  • Change from Baseline (Day 1) in fasting insulin at Week 8 and 16(Week 8 and 16)
  • Change from Baseline (Day 1) in C-peptide at Week 8 and 16(Week 8 and 16)
  • Change from Baseline (Day 1) in QUICKI at Week 16(Week 16)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (144)

Loading locations...

相似试验

已完成
2 期
Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe HypertriglyceridemiaSevere Hypertriglyceridemia
NCT0454118689bio, Inc.86
终止
2 期
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension
NCT00832507Gilead Sciences162
已完成
2 期
GB001 in Adult Subjects With Moderate to Severe AsthmaAsthma
NCT03683576GB001, Inc, a wholly owned subsidiary of Gossamer Bio, Inc.481
终止
2 期
A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus InfectionChronic Hepatitis b
NCT05238844Antios Therapeutics, Inc2
终止
2 期
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus CoinfectionHepatitis B, ChronicHepatitis D
NCT04847440Antios Therapeutics, Inc40